Matthews P, Jones C J, Skinner J, Haughton M, de Micco C, Wynford-Thomas D
Department of Pathology, University of Wales College of Medicine, Cardiff CF14 4XN, UK.
J Pathol. 2001 Jun;194(2):183-93. doi: 10.1002/path.848.
Despite several recent studies, the biological status and clinical relevance of telomerase expression in tumours derived from the thyroid follicular cell remain controversial. This study has analysed a series of normal, benign, and malignant thyroid samples using two novel approaches: the use of purified epithelial cell fractions to eliminate false-positives due to telomerase-positive infiltrating lymphocytes; and the simultaneous measurement of telomere length to provide a clearer interpretation of telomere dynamics in thyroid neoplasia. The data obtained support the prediction that the epithelial component of non-neoplastic thyroid and of follicular adenomas is telomerase-negative, any positive results being explicable by lymphocyte infiltration. In contrast, many malignant tumours, both follicular and papillary, were telomerase-positive. However, serial dilution of extracts indicated a wide spectrum of activity in these cancers, possibly related to variation in the proportion of telomerase-positive cells. Furthermore, an unexpectedly high proportion were telomerase-negative, a finding which was not explicable by technical problems such as TRAP (telomeric repeat amplification protocol) assay sensitivity. Many of these apparently telomerase-negative tumours had abnormally long telomeres. Correlation of telomerase and telomere length data suggests that thyroid cancers fall into three biological groups: telomerase-positive lesions, consistent with the conventional model of telomere erosion followed by telomerase reactivation; telomerase-negative tumours, which maintain telomere length by a mechanism independent of telomerase; and telomerase-negative tumours which are still undergoing telomere erosion and may therefore be composed of mortal cancer cells. From a clinical standpoint, it is concluded that telomerase detection on unfractionated tissue, such as fine needle aspirates, is of no value as a marker of malignancy in follicular lesions, due to both low sensitivity and specificity.
尽管最近有多项研究,但甲状腺滤泡细胞来源肿瘤中端粒酶表达的生物学状态及临床相关性仍存在争议。本研究采用了两种新方法分析了一系列正常、良性及恶性甲状腺样本:使用纯化的上皮细胞组分以消除因端粒酶阳性浸润淋巴细胞导致的假阳性;同时测量端粒长度,以便更清晰地解读甲状腺肿瘤中端粒的动态变化。所获数据支持以下预测:非肿瘤性甲状腺及滤泡性腺瘤的上皮成分端粒酶呈阴性,任何阳性结果都可归因于淋巴细胞浸润。相比之下,许多恶性肿瘤,包括滤泡状和乳头状肿瘤,端粒酶呈阳性。然而,提取物的系列稀释表明这些癌症中的端粒酶活性范围广泛,这可能与端粒酶阳性细胞比例的变化有关。此外,出乎意料的是,有相当高比例的肿瘤端粒酶呈阴性,这一发现无法用诸如端粒重复序列扩增法(TRAP)检测灵敏度等技术问题来解释。许多这些明显端粒酶阴性的肿瘤端粒异常长。端粒酶和端粒长度数据的相关性表明,甲状腺癌可分为三个生物学组:端粒酶阳性病变,符合端粒侵蚀后再激活端粒酶的传统模型;端粒酶阴性肿瘤,通过独立于端粒酶的机制维持端粒长度;以及仍在经历端粒侵蚀、因此可能由终末分化癌细胞组成的端粒酶阴性肿瘤。从临床角度来看,得出的结论是,由于灵敏度和特异性较低,在未分级组织(如细针穿刺抽吸物)上检测端粒酶作为滤泡性病变恶性肿瘤的标志物并无价值。